Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.04 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: rovelizumab, efalizumab, lifitegrast | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 8 Parkinson's papers of 745 | 0.71 |
| pathways Reactome | 7 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 6178
Sealed predictions
- ITGB2 in dopamine neurons, braak-0.48 (p 0.190) → -0.12 (p 0.750)receipt 6185
Swarm cases
receipt 6185: ITGB2 in dopamine neurons, braak
- power
- full sample -0.38 (p 0.120, n 18), 95% CI -0.72 to +0.11. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.41 (p 0.095, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.41 (p 0.089, n 18). could be the mix.
- skeptic
- leave-one-out range -0.52 to -0.30, sign flips 0; without severely affected donors -0.38 (p 0.120, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ITGB2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts